Tranexamic acid

Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590) ) [1][2][3][4][5][6].

Product Specifications

CAS Number

[1197-18-8]

Product Name Alternative

Cyclocapron

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

AMPK; IGF-1R; Mitophagy; MMP; PROTAC Linkers

Type

Reference compound

Related Pathways

Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; PROTAC; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Tranexamic-acid.html

Purity

99.88

Solubility

DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)

Smiles

O=C([C@H]1CC[C@H](CN)CC1)O

Molecular Formula

C8H15NO2

Molecular Weight

157.21

Precautions

H315, H319, H335

References & Citations

[1]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234 (11) : 19121-19129.|[2]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3 (5) : 729-733.|[3]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17 (12) : 2174-2187.|[4]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[5]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320 (13) : 840-843.|[6]Zhen Li, et al., Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands, Chinese Chemical Letters, 2025, 111033, ISSN 1001-8417.